Latest Europe News

Paradigm Biopharmaceuticals has achieved 50% patient enrolment in its pivotal Phase 3 trial for injectable pentosan polysulfate sodium, advancing steadily towards an interim analysis expected in August 2026.

RocketBoots has secured a significant A$3.3 million activation contract with a leading multinational retailer, marking the start of a global deployment phase that complements its existing SaaS agreement and promises near-term revenue growth.

Genetic Signatures is undertaking a major organisational restructure to cut costs by $5 million and sharpen its commercial focus, aiming to accelerate growth in its diagnostic product offerings.

Cynata Therapeutics has completed the 100-day primary evaluation period for its Phase 2 trial of CYP-001 in acute graft versus host disease, with results expected in June 2026. This milestone marks a critical step for the biotech’s lead cell therapy candidate in a condition with few effective treatments.

EML Payments has appointed Adam Olding as its Global CEO, marking a pivotal step in its EML 2.0 transformation and signalling strengthened leadership to drive growth. Concurrently, regulatory developments around its Australian banking licence application introduce new compliance dynamics.

Ava Risk Group has announced a $7 million strategic investment from US-based Hale Capital to fuel its expansion into the US federal security market and accelerate product development. This partnership aims to position Ava as a global leader in critical infrastructure protection with a strong US presence.

Fortuna Metals Limited (ASX:FUN) reports a major high-grade rutile discovery at its Mkanda project in Malawi, positioning itself to meet rising demand from aerospace and emerging robotics sectors amid a tightening global titanium market.

4DMedical has achieved CE Mark certification for its groundbreaking CT:VQ™ ventilation-perfusion imaging technology, unlocking the vast European market. The company also raised $83 million to fund rapid expansion across the EU.

Titomic Limited has secured a significant $1.7 million purchase order from the Netherlands’ Royal NLR, reinforcing its foothold in European aerospace and defense additive manufacturing.

International Graphite Limited (IG6) has partnered with Italian chemical giant ALKEEMIA to establish a cutting-edge graphite processing facility in Italy, targeting production by late 2027. This joint venture aims to secure Europe's graphite supply chain amid rising demand and regulatory pressures.

Ava Risk Group secures key government contracts and expands its technology trials in Australia, the US, and the Middle East during Q3 FY2026, reinforcing its position in critical infrastructure security.

Eden Innovations reports robust expansion of its EdenCrete® concrete additives in North and South America, driven by new contracts with major ready-mix concrete producers. The company’s low-carbon products are gaining traction amid growing sustainability demands.